Metformin and gynecologic cancers

Obstetrical and Gynecological Survey

Volumn 69, Issue 8, 2014, Pages 477-489

  Stine, Jessica E ^a   Bae Jump, Victoria ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER PREVENTION; DISEASE ASSOCIATION; DRUG MECHANISM; ENDOMETRIUM CANCER; GENERAL PRACTITIONER; GYNECOLOGIC CANCER; GYNECOLOGIST; HUMAN; INSULIN RESISTANCE; MEDLINE; META ANALYSIS (TOPIC); NONHUMAN; OBESITY; OBSTETRICIAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREOPERATIVE EVALUATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); ENDOMETRIAL NEOPLASMS; FEMALE; OVARIAN NEOPLASMS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; METFORMIN; OBESITY; OVARIAN NEOPLASMS;

EID: 84906671466     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0000000000000092     Document Type: Article

References (124)

1. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491-497.
2. National Health Examination Survey Data. Available at: http://www.cdc.gov/nchs/data/hestat/obesity-adult-09-10/obesity-adult-09-10.htm.
3. A.D. Association, ed. National Diabetes Fact Sheet 2011. Centers for Disease Control; 2011.
4. National Cancer Institute. National Cancer Institute at the National Institutes of Health fact sheet on obesity and cancer risk. National Cancer Institute Web site. Available at: http://www.cancer.gov/cancertopics/factsheet/ Risk/. Obesity. 2014. Reviewed April 22, 2014.
5. Coppieters KT, von Herrath MG. Metabolic syndrome-removing roadblocks to therapy: antigenic immunotherapies. Mol Metab. 2014;3:275-283.
6. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996;88:1127-1135. (Pubitemid 26274607)
7. Okwan-Duodu D, Umpierrez GE, Brawley OW, et al. Obesitydriven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages. Am J Cancer Res. 2013;3:21-33.
8. Jensen H. Endometrial carcinoma. A retrospective, epidemiological study. Dan Med Bull. 1985;32:219-228. (Pubitemid 15014491)
9. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. (Pubitemid 34437694)
10. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and metaanalysis. Cancer Prev Res (Phila). 2010;3:1451-1461.
11. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330: 1304-1305. (Pubitemid 40813563)
12. Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol. 2010;116:92-98.
13. Gunter MJ, Hoover DR, Yu H, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17:921-929. (Pubitemid 351536424)
14. Gehrig PA, Bae-Jump VL. Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol. 2010;116:187-194.
15. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-1596.
16. Quinn BJ, Kitagawa H, Memmott RM, et al. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab. 2013;24:469-480.
17. Dronavalli S, Ehrmann DA. Pharmacologic therapy of polycystic ovary syndrome. Clin Obstet Gynecol. 2007;50:244-254. (Pubitemid 46279865)
18. Bowker SL,Majumdar SR, Veugelers P, et al. Increased cancerrelatedmortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254-258. (Pubitemid 44106500)
19. Libby G, Donnelly LA, Donnan PT, et al. Newusers of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620-1625.
20. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012;2:778-790.
21. Bonanni B, Puntoni M, Cazzaniga M, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012;30:2593-2600.
22. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, et al. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2013;71:63-72.
23. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 2010;3:1077-1083.
24. MacKenzie MJ, Ernst S, Johnson C, et al. A phase I study of temsirolimus and metformin in advanced solid tumours. Invest New Drugs. 2012;30:647-652.
25. Nobes JP, Langley SE, Klopper T, et al. A prospective, randomized pilot study evaluating the effects ofmetformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2012;109:1495-1502.
26. He X, Esteva FJ, Ensor J, et al. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. 2012;23:1771-1780.
27. He XX, Tu SM, Lee MH, et al. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol. 2011;22:2640-2645.
28. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137:25-33. (Pubitemid 34705373)
29. Collier CA, Bruce CR, Smith AC, et al. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am J Physiol Endocrinol Metab. 2006;291:E182-E189. (Pubitemid 44035324)
30. Miller RA, Chu Q, Xie J, et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494:256-260.
31. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334: 574-579. (Pubitemid 126537875)
32. Shin NR, Lee JC, Lee HY, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014; 63:727-735.
33. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642-1646. (Pubitemid 41780780)
34. Pierotti MA, Berrino F, Gariboldi M, et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene. 2012;12:1475-1487.
35. Berns EM, Klijn JG, Henzen-Logmans SC, et al. Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. Int J Cancer. 1992; 52:218-224.
36. van Dam PA, Vergote IB, Lowe DG, et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol. 1994;47:914-919.
37. Brokaw J, Katsaros D, Wiley A, et al. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors. 2007;25:346-354. (Pubitemid 351194033)
38. Spentzos D, Cannistra SA, Grall F, et al. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer. 2007;14:781-790. (Pubitemid 350074066)
39. McCampbell AS, Broaddus RR, Loose DS, et al. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 2006;12:6373-6378. (Pubitemid 44799707)
40. An HJ, Lee YH, Cho NH, et al. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology. 2002; 41:437-445.
41. Contreras CM, Gurumurthy S, Haynie JM, et al. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res. 2008;68:759-766. (Pubitemid 351206752)
42. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924-930.
43. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer. 2003;10:203-208. (Pubitemid 36758649)
44. Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA. 2009;106:4834-4839.
45. Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005;65:10669-10673. (Pubitemid 41713332)
46. Catasus L, Gallardo A, Cuatrecasas M, et al. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol. 2009;22: 522-529.
47. Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol. 2009;113:370-373.
48. Miyake T, Yoshino K, Enomoto T, et al. PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences. Cancer Lett. 2008;261:120-126.
49. Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011;1:170-185.
50. Sun M, Wang G, Paciga JE, et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 2001;159:431-437. (Pubitemid 32751073)
51. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995;64:280-285.
52. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21:99-102. (Pubitemid 29036292)
53. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005;11:2875-2878. (Pubitemid 40525186)
54. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3?-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001;61:7426-7429. (Pubitemid 32995029)
55. Saito M, Okamoto A, Kohno T, et al. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer. 2000;85:160-165. (Pubitemid 30023061)
56. Iglesias DA, Yates MS, van der Hoeven D, et al. Another surprise from metformin: novel mechanism of action via K-ras influences endometrial cancer response to therapy. Mol Cancer Ther. 2013;12:2847-2856.
57. Sarfstein R, Friedman Y, Attias-Geva Z, et al. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or-independent manners. PLoS One. 2013;8:e61537.
58. Hanna RK, Zhou C, Malloy KM, et al. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol. 2012;125:458-469.
59. Dong L, Zhou Q, Zhang Z, et al. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. J Obstet Gynaecol Res. 2012;38:1077-1085.
60. Erdemoglu E, Guney M, Giray SG, et al. Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol. 2009; 145:195-199.
61. Tan BK, Adya R, Chen J, et al. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab. 2011;96:808-816.
62. Zhang Z, Dong L, Sui L, et al. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer. 2011;21:213-221.
63. Mu N, Wang Y, Xue F. Metformin: a potential novel endometrial cancer therapy. Int J Gynecol Cancer. 2012;22:181.
64. Wu B, Li S, Sheng L, et al. Metformin inhibits the development and metastasis of ovarian cancer. Oncol Rep. 2012;28:903-908.
65. Yasmeen A, Beauchamp MC, Piura E, et al. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol. 2011;121:492-498.
66. Liao H, Zhou Q, Gu Y, et al. Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol Rep. 2012;27:1873-1878.
67. Rattan R, Giri S, Hartmann LC, et al. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2011;15:166-178.
68. Rattan R, Graham RP, Maguire JL, et al. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011;13: 483-491.
69. Li C, Liu VW, Chan DW, et al. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells. Int J Gynecol Cancer. 2012;22:15-22.
70. Chan DK, Miskimins WK. Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures. J Ovarian Res. 2012;5:19.
71. Erices R, Bravo ML, Gonzalez P, et al. Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells. Reprod Sci. 2013;20:1433-1446.
72. Shank JJ, Yang K, Ghannam J, et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol. 2012;127: 390-397.
73. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. GynecolOncol. 2008;110:246-250.
74. Algire C, Zakikhani M, Blouin MJ, et al. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer. 2008;15:833-839.
75. Phoenix KN, Vumbaca F, Fox MM, et al. Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res Treat. 2009;2:333-344.
76. Jackson A, Zhong Y, Zhou C, et al. Metformin had increased efficacy under obese conditions in a novel genetically engineered mouse model of serous ovarian cancer. Paper presented at: Annual Meeting of the Society of Gynecologic Oncology. Tampa, FL; 2014.
77. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
78. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
79. Ko EM, Walter P, Clark L, et al. The complex triad of obesity, diabetes and race in type I and II endometrial cancers: prevalence and prognostic significance. Gynecol Oncol. 2014;133:28-32.
80. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors?J Clin Oncol. 2013;31:2607-2618.
81. Schmandt RE, Iglesias DA, Co NN, et al. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol. 2011;205:518-525.
82. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and metaanalysis of prospective observational studies. Lancet. 2008;371: 569-578. (Pubitemid 351232031)
83. Chia VM, Newcomb PA, Trentham-Dietz A, et al. Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer. 2007;17:441-446. (Pubitemid 46426761)
84. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638. (Pubitemid 36459468)
85. Steiner E, Plata K, Interthal C, et al. Diabetes mellitus is a multivariate independent prognostic factor in endometrial carcinoma: a clinicopathologic study on 313 patients. Eur J Gynaecol Oncol. 2007;28:95-97. (Pubitemid 46697776)
86. Arem H, Park Y, Pelser C, et al. Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. J Natl Cancer Inst. 2013;105:342-349.
87. Ward KK, Shah NR, Saenz CC, et al. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol. 2012;126:176-179.
88. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17. (Pubitemid 13194678)
89. Bodmer M, Becker C, Meier C, et al. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol. 2011;123:200-204.
90. Romero IL, McCormick A, McEwen KA, et al. Relationship of type II diabetes andmetformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012;119:61-67.
91. Kumar S, Meuter A, Thapa P, et al. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer. 2013;119:555-562.
92. Currie CJ, Poole CD, Jenkins-Jones S, et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012;35:299-304.
93. Becker C, Jick SS, Meier CR, et al. Metformin and the risk of endometrial cancer: a case-control analysis. Gynecol Oncol. 2013;129:565-569.
94. Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Metformin use and endometrial cancer survival. Gynecol Oncol. 2014;132: 236-240.
95. Ko EM, Walter P, Jackson A, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol. 2014;132:438-442.
96. Ko E, Stürmer T, Hong JL, et al. Metformin and the risk of endometrial cancer: a population-based cohort study. Paper presented at: Annual Meeting of the Society of Gynecologic Oncology. Tampa, FL; 2014.
97. Cancer.org. Survival rates for ovarian cancer, by stage. Available at: http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer- survival-rates. 2014.
98. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20:207-225. (Pubitemid 43380597)
99. American Cancer Society. Cancer Facts and Figures. 2012.
100. MarkmannS,GerberB,Briese V.Prognostic value ofCa 125 levels during primary therapy. Anticancer Res. 2007;27:1837-1839. (Pubitemid 46954684)
101. Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2012;5:901-910.
102. Yang HS, Yoon C, Myung SK, et al. Effect of obesity on survival of women with epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer. 2011;21:1525-1532.
103. Olsen CM, Green AC, Whiteman DC, et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007;43:690-709. (Pubitemid 46502901)
104. Lubin F,Chetrit A, Freedman LS, et al. Bodymass index at age 18 years and during adult life and ovarian cancer risk. Am J Epidemiol. 2003;157:113-120. (Pubitemid 36077442)
105. Engeland A, Bjorge T, Selmer RM, et al. Height and body mass index in relation to total mortality. Epidemiology. 2003;14: 293-299. (Pubitemid 40417080)
106. Brenner DE, Hawk E. Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions. Cancer Prev Res (Phila). 2013;6:71-73.
107. Fabian CJ, Kimler BF, Anderson J, et al. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res. 2004;10:5403-5417. (Pubitemid 39100477)
108. Patel KR, Brown VA, Jones DJ, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010;70:7392-7399.
109. Heymach JVK, Shackleford TJ, Tran HT, et al. Effect of low-fat diets on plasma levels of NF-kappaB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila). 2011;4:1590-1598.
110. Simoneau AR, Gerner EW, Phung M, et al. Alphadifluoromethylornithine and polyamine levels in the human prostate:results of a phase IIa trial. J Natl Cancer Inst. 2001; 93:57-59. (Pubitemid 32060891)
111. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat. 2011;128:783-794.
112. Bullwinkel J, Baron-Luhr B, Ludemann A, et al. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol. 2006;206:624-635. (Pubitemid 43191037)
113. Niraula S, Dowling RJ, Ennis M, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat. 2012;135:821-830.
114. Cazzaniga M, DeCensi A, Pruneri G, et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer. 2013;109:2792-2797.
115. Schuler KM, Rambally BS, Difurio MJ, et al. A Pre-operative Window Study of Metformin for the Treatment of Endometrial Carcinoma. Proceedings of the 2013 Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; 2013.
116. Schuler K, Rambally BS, DiFurio MJ, et al. Biological Effects of Metformin in a Pre-operative Window Clinical Trial for Endometrial Cancer. Proceedings of the 2014 Annual Meeting of the Society of Gynecologic Oncology. Tampa, FL; 2014.
117. SolimanPT,BroaddusR,WestinS, et al. Phase 0 Study: Prospective Evaluation of theMolecular Effects of Metformin on the Endometrium in Women With Newly Diagnosed Endometrial Cancer. Society of Gynecologic Oncologists AnnualMeeting onWomen's Cancer. Society of Gynecologic Oncologists; 2013:S15.
118. Wang DS, Jonker JW, Kato Y, et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002;302:510-515. (Pubitemid 34787213)
119. Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005;20:379-386.
120. Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res. 2005;22:255-259. (Pubitemid 40487209)
121. Terada T, Masuda S, Asaka J, et al. Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006;23:1696-1701. (Pubitemid 44200531)
122. Masuda S, Terada T, Yonezawa A, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006;17:2127-2135. (Pubitemid 44141902)
123. Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos. 2007;35:1956-1962. (Pubitemid 47481592)
124. Han T, Proctor W, Costales C, et al. The Role of the Organic Cation Transporter 1 (OCT1) and Plasma Membrane Monoamine Transporter (PMAT) in Metformin Apical Uptake in Caco-2 Cells. Proceedings of the Annual Meeting of the American Association of Pharmaceutical Scientists. 2011.